ENOCHIAN BIOSCIENCES INC (ENOB) Stock Price, Forecast & Analysis
USA - NASDAQ:ENOB - US29350E1047 - Common Stock
ENOB Key Statistics, Chart & Performance
The current stock price of ENOB is 0.7 USD. In the past month the price increased by 47.99%. In the past year, price decreased by -75.52%.
ENOB Latest News, Press Relases and Analysis
ENOB Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.83 | 397.78B | ||
| AMGN | AMGEN INC | 15.48 | 182.21B | ||
| GILD | GILEAD SCIENCES INC | 14.96 | 152.07B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.72 | 110.05B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.99 | 71.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 886.18 | 59.24B | ||
| INSM | INSMED INC | N/A | 40.94B | ||
| NTRA | NATERA INC | N/A | 28.37B | ||
| BIIB | BIOGEN INC | 9.53 | 23.39B | ||
| INCY | INCYTE CORP | 16.85 | 21.12B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.4 | 20.77B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 35.24 | 14.61B |
Related stock screener links
About ENOB
Company Profile
Enochian Biosciences, Inc. is a pre-clinical stage biotechnology company, which engages in the development of genetically modified cellular and immune-therapy technologies used for the treatment of infectious diseases and cancer. The company is headquartered in Los Angeles, California and currently employs 11 full-time employees. The company went IPO on 2014-11-18. The firm is focused on developing allogeneic cell and gene therapies to promote stronger immune system responses for long-term or life-long cancer remission in cancers and to treat or cure infectious diseases, such as Human Immunodeficiency Virus (HIV) and Hepatitis B virus (HBV) infection. The Allogeneic Cell Therapy platform has a human immune system, which is designed to recognize the self and destroy otherness or non-self, such as bacteria, viruses and cancer cells. The Company’s product candidates include ENOB-HV-01, which utilizes a cellular- and immunotherapy approach that could provide both preventative and therapeutic vaccines for HIV and ENOB-DC-11, which is a genetically modified allogeneic dendritic cell therapeutic vaccine as product for long-term remission of solid tumors. The company is also exploring ENOB-HV-21, a treatment for HIV with allogeneic natural killer (NK) and gamma delta t-cells (GDT).
Company Info
ENOCHIAN BIOSCIENCES INC
Century City Medical Plaza, 2080 Century City East
Los Angeles CALIFORNIA 90067 US
CEO: Mark Dybul
Employees: 11
Phone: 14539179840.0
ENOCHIAN BIOSCIENCES INC / ENOB FAQ
What does ENOB do?
Enochian Biosciences, Inc. is a pre-clinical stage biotechnology company, which engages in the development of genetically modified cellular and immune-therapy technologies used for the treatment of infectious diseases and cancer. The company is headquartered in Los Angeles, California and currently employs 11 full-time employees. The company went IPO on 2014-11-18. The firm is focused on developing allogeneic cell and gene therapies to promote stronger immune system responses for long-term or life-long cancer remission in cancers and to treat or cure infectious diseases, such as Human Immunodeficiency Virus (HIV) and Hepatitis B virus (HBV) infection. The Allogeneic Cell Therapy platform has a human immune system, which is designed to recognize the self and destroy otherness or non-self, such as bacteria, viruses and cancer cells. The Company’s product candidates include ENOB-HV-01, which utilizes a cellular- and immunotherapy approach that could provide both preventative and therapeutic vaccines for HIV and ENOB-DC-11, which is a genetically modified allogeneic dendritic cell therapeutic vaccine as product for long-term remission of solid tumors. The company is also exploring ENOB-HV-21, a treatment for HIV with allogeneic natural killer (NK) and gamma delta t-cells (GDT).
Can you provide the latest stock price for ENOCHIAN BIOSCIENCES INC?
The current stock price of ENOB is 0.7 USD.
Does ENOB stock pay dividends?
ENOB does not pay a dividend.
What is the ChartMill technical and fundamental rating of ENOB stock?
ENOB has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What is the GICS sector and industry of ENOB stock?
ENOCHIAN BIOSCIENCES INC (ENOB) operates in the Health Care sector and the Biotechnology industry.
What is the Price/Earnings (PE) ratio of ENOCHIAN BIOSCIENCES INC (ENOB)?
ENOCHIAN BIOSCIENCES INC (ENOB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2).
Can you provide the market cap for ENOCHIAN BIOSCIENCES INC?
ENOCHIAN BIOSCIENCES INC (ENOB) has a market capitalization of 40.80M USD. This makes ENOB a Nano Cap stock.
ENOB Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to ENOB. When comparing the yearly performance of all stocks, ENOB is a bad performer in the overall market: 96.77% of all stocks are doing better.
ENOB Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ENOB. ENOB may be in some trouble as it scores bad on both profitability and health.
ENOB Financial Highlights
Over the last trailing twelve months ENOB reported a non-GAAP Earnings per Share(EPS) of -2. The EPS decreased by -149.93% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |